Sabestomig (AZD7789)
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed or Refractory Classical Hodgkin Lymphoma
Conditions
Relapsed or Refractory Classical Hodgkin Lymphoma
Trial Timeline
Mar 18, 2022 → Sep 4, 2025
NCT ID
NCT05216835About Sabestomig (AZD7789)
Sabestomig (AZD7789) is a phase 1 stage product being developed by AstraZeneca for Relapsed or Refractory Classical Hodgkin Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT05216835. Target conditions include Relapsed or Refractory Classical Hodgkin Lymphoma.
What happened to similar drugs?
2 of 20 similar drugs in Relapsed or Refractory Classical Hodgkin Lymphoma were approved
Approved (2) Terminated (2) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05216835 | Phase 1 | Completed |
Competing Products
20 competing products in Relapsed or Refractory Classical Hodgkin Lymphoma